Zhejiang University: Pancreatic Neoplasms trials

The registry lists 23 Pancreatic Neoplasms studies with Zhejiang University as lead sponsor. 16 are open to participants now and 0 have results posted.

Early Phase 1 2Phase 1 6Phase 2 14No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic CancerNot yet recruitingNCT07736612Phase 1/2
• IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic CancerNot yet recruitingNCT07415525Phase 2
• Laryngopharyngeal Injury After Endotracheal Intubation Under General AnesthesiaRecruitingNCT07359586
• Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.Not yet recruitingNCT06888674Phase 1/2
• Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.Not yet recruitingNCT06888648Phase 1/2
• HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer PatientsRecruitingNCT06770452Phase 2
• Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic CancerNot yet recruitingNCT06759090Phase 2
• Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic CancerRecruitingNCT06572813Phase 1/2
• Research of the Application of Artificial Intelligence Model "PANDA"Not yet recruitingNCT06528223Not applicable
• A Trail of Second-line Chemotherapy Sequential NKG2D CAR-NK Cell Therapy for Pancreatic CancerRecruitingNCT06503497Early Phase 1
• Early Diagnosis of Pancreatic Cancer Via Deciphering Multi-modal Immunological SignaturesNot yet recruitingNCT06495749
• Endoscopic Ultrasound (EUS) Intratumoral Injection of CAR-NK Cells in the Treatment of Advanced Pancreatic CancerRecruitingNCT06478459Early Phase 1
• Irinotecan Liposome for Resectable Pancreatic Cancer With or Without AddebelizumabNot yet recruitingNCT06172036Phase 2
• Fluorescent Navigation Technology in Radical Resection of Pancreatic CancerNot yet recruitingNCT06168552Phase 1/2
• Enucleation of Pancreatic Tumor by Blocking Abdominal Trunk and Superior Mesenteric ArteryRecruitingNCT06164769Not applicable
• Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic CancerRecruitingNCT05162118Phase 1/2
• Multimodal Managements for Metastatic Pancreatic Cancer.CompletedNCT06967233
• Research of the Application of Pancreatic Cancer Screening Artificial Intelligence Model "PANDAPro"Active, not recruitingNCT06643715Not applicable
• Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic CancerCompletedNCT03983057Phase 2
• Combination of Anti-PD-1 Antibody and Chemotherapy in Metastatic Pancreatic CancerCompletedNCT03977272Phase 2
• GS Regimen as the First-line Chemotherapy in Chinese Advanced PC PatientsCompletedNCT03869294
• Second-Line Oxaliplatin and Irinotecan Versus Irinotecan Alone for Gemcitabine and S-1 Refractory Pancreatic CancerCompletedNCT02558868Phase 2
• S-1 and and Gemcitabine vs Gemcitabine Alone as Adjuvant Chemotherapy for Patients With Resected Pancreatic CancerCompletedNCT02131493Phase 2